LPL Financial’s Cidara Therapeutics CDTX Stock Holding History

LPL Financial’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,027	Closed	-$2.11M	–	5902
2025 Q3	$2.11M	Buy	+22,027	New	+$1.41M	﹤0.01%	3269

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

LPL Financial's CDTX Position: Q4 2025 in Review

LPL Financial sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 22,027 shares — an estimated $2.11M sold.

LPL Financial first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $2.11M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

LPL Financial reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
LPL Financial sold 22,027 Cidara Therapeutics shares in Q4 2025, an estimated $2.11M.
LPL Financial first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
LPL Financial's Cidara Therapeutics position peaked at $2.11M in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on LPL Financial's 13F filing for Q4 2025, filed 11 Feb 2026.